Background. A pathogenic role of intraglomerular plasmin bound to nephritogenic antigen (nephritis-associated plasmin receptor, NAPlr) and resistant to physiologic inhibitors such as α 2 -antiplasmin (α 2 -AP) has recently been proposed in acute poststreptococcal glomerulonephritis (APSGN). To confirm this concept, we analysed the urinary profile of plasmin cascade in APSGN patients. Methods. Urine samples from 10 patients with APSGN, 12 patients with IgA nephropathy (IgAN), 10 patients with streptococcal infection without nephritis (SI) and 10 healthy control subjects were analysed. The α 2 -AP-resistant plasmin activity was assessed by a chromogenic assay after α 2 -AP was added to each urine sample. Urinary plasminogen activator (PA) and plasmin were further analysed by polyacrylamide gel zymography. Urinary NAPlr was assessed by western blot analysis in selected samples. Results. Urinary α 2 -AP-resistant plasmin activity corrected for creatinine concentration (units/g · creatinine) was significantly higher in patients with APSGN (2.99 ± 0.63) than in patients with IgAN (1.02 ± 0.20, P < 0.01), SI (0.79 ± 0.17, P < 0.01), or in healthy control subjects (0.73 ± 0.18, P < 0.01). This tendency was confirmed by casein gel zymography. However urinary PA activity assessed by plasminogen-casein gel zymography did not differ between groups. NAPlr was detected in the urine of APSGN patients. Conclusions. We found elevated urinary plasmin activity resistant to α 2 -AP, which may be due to urinary excretion of NAPlr in patients with APSGN. This result supports the pathogenic role of the NAPlr-plasmin complex in the development of APSGN. Furthermore, α 2 -AP-resistant urinary plasmin activity may be useful as a diagnostic marker for APSGN.
Introduction
Acute poststreptococcal glomerulonephritis (APSGN) is a sequela of streptococcal infection thought to be induced by a certain streptococcal antigen [1] . Identification of a causative antigen is critical for the elucidation of the mechanism of this disease; however, it remains a matter of debate [2] [3] [4] [5] [6] . Among known nephritogenic antigens, leading candidates include nephritis-associated plasmin receptor (NAPlr) [5, 6] and streptococcal pyrogenic exotoxin B (SPEB) [3, 4] . Despite the controversy regarding which is the principal antigen [7, 8] , NAPlr and SPEB share a common function. Both possess plasmin-binding capacity and may mediate glomerular damage via plasmin activity [3, 9, 10] . In general, the free form of plasmin is tightly regulated by physiologic inhibitors such as α 2 -antiplasmin (α 2 -AP) in vivo [11, 12] . However, once plasmin binds to its receptor, it has been shown to be stabilized and resistant to physiologic inhibitors in vitro [11] . We reported involvement of such a mechanism in APSGN by showing prominent α 2 -AP-resistant glomerular plasmin activity in a distribution identical to that of NAPlr deposition in the renal biopsy tissues from APSGN patients [9] . Plasmin may degrade and injure a glomerular basement membrane via its proteolytic activity, but may also mediate inflammation by activating and accumulating monocytes and neutrophils in situ, thereby contributing to the formation of early glomerular lesions of APSGN.
NAPlr-bound plasmin should be stable and detectable in the urine of APSGN patients and may be a diagnostic marker. To confirm this, we evaluated urinary plasmin 
Subjects and methods

Patients
Supernatants of freshly voided urine samples from 10 patients with APSGN, 12 patients with IgAN, 10 patients with SI and 10 healthy control subjects were used. Characteristics of APSGN, SI and IgAN patients are shown in 
Chromogenic plasmin assay
Urinary plasmin activity was measured with a plasminspecific substrate, Tos-Gly-Pro-Lys-p-nitroanilide (Chromozym PL; Roche Molecular Biochemicals, Indianapolis, IN, USA), essentially according to the manufacturer's instructions. In brief, 10 µl of 100 mIU/ml α 2 -AP (Merck, Darmstadt, Germany) and 50 µl urine sample were premixed in a 96-well plate, and buffer and chromogenic substrate solution were added to a final volume of 120 µl. An increase in absorbance at 405 nm after 2 h was calculated. Sample values were determined from standard curves generated with the use of serially diluted human plasmin (Wako Pure Chemical Industries, Osaka, Japan). Results were corrected for urinary creatinine concentration and expressed as units/g · creatinine (U/g · Cr). In addition, the inhibitory ability of α 2 -AP in our assay system was evaluated by comparing the chromogenic results of plasmin standards with or without addition of α 2 -AP (10 µl of 100 mIU/ml solution). Furthermore, in some urine samples (three IgAN patients and three healthy controls), chromogenic results with or without plasmin addition (5 ng of plasmin, which would correspond to the urinary plasmin activity level of 1.74 U/g · Cr at a urinary Cr concentration of 100 mg/dl) were compared to confirm the inhibitory efficacy of α 2 -AP against free plasmin.
Gel zymography for plasminogen activator (PA)/plasmin activity
PA and plasmin activities were assessed by polyacrylamide gel zymography as described previously [13] . Urine samples containing 2 µg and 40 µg creatinine were applied for plasminogen-casein and casein zymographic gels, respectively. Samples containing 40 µg creatinine were concentrated with centrifugal filter units (Ultrafree-MC; nominal molecular-weight limit: 10 kDa; Millipore, Bedford, MA, USA). Each sample was separated under non-reducing conditions on a 10% SDS-polyacrylamide gel containing 2 mg/ml casein (Sigma-Aldrich Co., St Louis, MO, USA) with or without 10 µg/ml plasminogen (Sigma-Aldrich). After being washed with 2.5% Triton X-100, gels were incubated in substrate buffer (0.1 M glycine, pH 8.3) at 37
• C. The incubation time for plasminogen-casein gels was 12 h but that for casein gels was 36 h. Gels were then stained with 0.002% Coomassie blue. The density of each lytic band was quantified with image analysing software (CS Analyzer Version 2.0; ATTO, Tokyo, Japan). Linearization of the assay was ensured with the use of serially diluted human plasmin or low molecular weight (33 kDa) human urokinase-type plasminogen activator (uPA) (CalbiochemMerck KgaA, Darmstadt, Germany) as a standard. To identify the band representing plasmin activity, adsorption tests were performed. Rabbit anti-human plasmin(ogen) antibody (Nordic Immunological Laboratories, Tilburg, The Netherlands) was immobilized with the use of a protein G immunoprecipitation kit (Seize X; Pierce, Rockford, IL, USA). Urine samples with or without immobilized antibody treatment were analysed by casein gel zymography.
Western blot analysis of NAPlr
The presence of NAPlr in urine was analysed by western blotting. We could analyse urine samples from all healthy controls and SI patients, and also from selected patients with APSGN (patients 1, 2, 3, 6 and 8) and IgAN (patients 3, 5, 6, 7, 9, 10 and 12), because of the limitation in the amount of collected urine sample for this study. Urine samples containing 40 µg creatinine (concentrated with Ultrafree-MC centrifugal filter units) were subjected to 10% SDS-PAGE, and proteins were transferred to a PVDF membrane. After being blocked with 5% skim milk in PBS containing 0.1% Tween 20 (PBS-T) for 1 h, the membrane was incubated with an anti-NAPlr antibody (5 µg/ml in 5% skim milk/PBS-T) for 1 h. The generation and the specificity of mouse anti-NAPlr monoclonal antibody (1F10) have recently been described [14] . After being washed in PBS-T, the membrane was incubated in peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich) for 1 h, and reactive bands were detected with the ECL Plus detection kit (Amersham Biosciences, Piscataway, NJ, USA).
Statistical analysis
All values are expressed as mean ± standard error (SE). Generally, Student's t-test was used to evaluate differences in mean values between groups. However, in the assay of variation of urinary plasmin activity overtime, the Wilcoxon signed rank test was used. Differences were considered significant if the two-tailed P value was <0.05.
Results
Chromogenic assay of plasmin activity
Compared to the strong positive linear regression of the chromogenic results by plasmin standards (Y = 0.001 + 0.02 * X, r = 0.999, P < 0.0001), addition of α 2 -AP sufficiently inhibited the chromogenic reaction by plasmin standards up to the concentration level of 0.3 µg/ml (corresponding to the urinary plasmin activity level of 5.22 U/g · Cr at a urinary Cr concentration of 100 mg/dl) ( Figure 1A) . Moreover, the differences in the assay results between the crude urine samples and the samples with exogenous plasmin were minimal (1.26 ± 0.26 versus 1.35 ± 0.39), suggesting that α 2 -AP effectively inhibits the free plasmin in the present assay system. α 2 -AP-resistant urinary plasmin activity was significantly higher in APSGN patients (2.99 ± 0.63 U/g · Cr) than in IgAN patients (1.02 ± 0.20, P < 0.01), SI patients (0.79 ± 0.17, P < 0.01) or in healthy controls (0.73 ± 0.18, P < 0.01) ( Figure 1B) . Furthermore, in four APSGN patients from whom urine samples were collected twice in the disease course, the activity levels were always higher in the early collected samples than in the later collected samples (2.82 ± 1.08 versus 1.58 ± 0.86, P = 0.07) ( Figure 1C ).
Gel zymography profile of PA/plasmin activity
By casein gel zymography, several bands were detected in APSGN and IgAN patients but not in SI patients or in healthy controls, and the plasmin standard showed a doublet-triplet band at ∼65-80 kDa (Figure 2A) . Aprotinin treatment inhibited all bands similarly (data not shown), whereas adsorption of urine samples with anti-plasmin(ogen) antibody selectively inhibited the Figure 2B ), suggesting that the band represents plasmin activity. Relative plasmin activity, as assessed by the density of the 80-kDa band, was similar to that determined by chromogenic assay ( Figure 2C) ; activity was higher in APSGN patients (6.70 ± 3.14) than in controls (0 ± 0), SI patients (0 ± 0) or in IgAN patients (1.00 ± 0.55).
80-kDa band (
Two bands (33 and 54 kDa) representing low molecular weight and high molecular weight uPA were identified by plasminogen-casein gel zymography ( Figure 3A) ; these bands were inhibited when amiloride (a uPA inhibitor) was added to the substrate buffer or in the absence of plasminogen (data not shown). Plasmin and tPA activities were not detected in plasminogen-casein zymographic gels under our assay conditions. Relative total PA activity, as assessed by the density sum of each band, was higher in APSGN patients (1.44 ± 0.25) than in IgAN patients (1.21 ± 0.12), SI patients (0.90 ± 0.22) or in healthy controls (1.00 ± 0.20), but differences between these four groups were not significant ( Figure 3B ).
Urinary NAPlr
Faint but distinct bands were detected at the predicted position of NAPlr (43 kDa) by western blot analysis of urine samples from some APSGN patients (three out of five patients analysed), but none in patients from other groups (Figure 4 ).
Discussion
We recently found that the nephritogenic antigen for APSGN, which we termed NAPlr, was the same entity as plasmin receptor of group A streptococcus [5, 6] . Furthermore, we showed that plasmin activity distributed identically with NAPlr in glomeruli of APSGN patients by in situ zymography (see supplementary figure, available online) [9] . These results indicate that glomerular bound NAPlr may bind to plasmin and maintain its proteolytic activity, thereby contributing to the development of APSGN in vivo. Because the NAPlr-plasmin complex is stable and protected from physiologic inhibitors, urinary plasmin activity in patients with APSGN is presumed to be elevated. To evaluate this, we first investigated urinary plasmin activity by a chromogenic assay. In the assay, α 2 -AP was added to urine samples to evaluate the fraction of plasmin activity resistant to α 2 -AP, which may reflect the amount of the NAPlr-plasmin complex and the APSGN condition. Preaddition of α 2 -AP would also eliminate the influence of free plasmin generated during assay incubation. As we expected, α 2 -AP-resistant plasmin activity was elevated in APSGN patients. However, several patients with IgAN also showed high plasmin activity. This may be due to the effect of non-plasmin urinary serine proteases that are resistant to α 2-AP. The chromogenic substrate used in the plasmin assay (Tos-Gly-Pro-Lys-p-nitroanilide) has high affinity for and are sensitivity to plasmin, but it is not entirely specific; it is also sensitive to other serine proteases. Another possibility is that a certain proportion of IgAN cases were related to streptococcal infection. The possible contribution of chronic infection such as Haemophilus parainfluenzae [15] and Staphylococcus aureus [16] on IgAN has been reported. The important roles of streptococcal infection and glomerular NAPlr deposition have recently been demonstrated in more than a few HSPN patients [17] . The pathologic manifestations are similar in many aspects between HSPN and IgAN, so we do not think it a wild idea that some IgAN are induced by streptococcal infection similarly as HSPN. Indeed, there had been one report indicating the possible relationship between IgAN and streptococcal infection [18] .
To rule out the influence of other urinary proteases, we further analysed plasmin activity by casein gel zymography. Gel zymography offers the molecular weight and is useful for the specific identification of plasmin activity. Results of casein gel zymography were similar to those of the chromogenic assay, but the difference between APSGN and IgAN patients was not significant (P = 0.07). This may due to differences in the sensitivity and specificity of these assays. The sensitivity of casein gel zymography is relatively poor (long incubation times and a urine concentrating step are necessary to obtain obvious bands). In addition, casein gel zymography may identify active plasmin (free or Plr-bound form) and also inactive plasmin bound to plasmin inhibitors such as α 2 -AP due to non-specific decomposition during SDS-PAGE.
Contrary to the results of casein gel zymography, plasminogen-casein gel zymography did not show significant differences between the four groups, confirming that significant elevation of urinary plasmin activity was not due to differences in PA activity. Although the difference was not significant, mean uPA activity was higher in APSGN. This may be due to the prominent glomerular infiltration of macrophages in APSGN [19] ; macrophages are known to secrete uPA [20] .
The concomitant existence of α 2 -AP-resistant plasmin activity and NAPlr in the urine of APSGN patients suggests that NAPlr and plasmin are excreted in the urine as a complex. Indeed, plasmin receptor (NAPlr) has been shown to bind to plasmin and maintain plasmin's proteolytic activity by protecting it from physiologic inhibitors in vitro [5, 11] . Although no bands were detected at the expected size of the complex (∼120 kDa), the NAPlr-plasmin complex was found to dissociate during SDS-PAGE in our preliminary experiments (data not shown).
Although the sample number analysed in the present study was too small to reach the definite conclusion, our results indicate that urinary plasmin activity may serve as a supportive diagnostic marker for APSGN. Differential diagnosis of severe APSGN from other renal diseases that manifest as acute nephritic syndrome, such as IgAN, rapidly progressive glomerulonephritis or lupus nephritis, is not always easy. Considering that the incidence of APSGN is higher in children and that the prognosis is generally good, avoiding invasive procedures such as renal biopsy is desirable. Not only as a diagnostic marker, the level of urinary plasmin activity may serve as a follow-up marker, because the level decreases rapidly over time reflecting the resolutional character of APSGN [19] .
In summary, we identified elevation of urinary plasmin activity resistant to α 2 -AP and urinary excretion of NAPlr in patients with APSGN. The results support our concept that NAPlr-bound plasmin plays a role in the pathogenesis of APSGN and offers information regarding the development of diagnostic markers for APSGN.
